- AbbVie has begun construction of a new API manufacturing facility in North Chicago, Illinois.
- The $195 million investment will expand U.S. manufacturing capacity and support production of future medicines in neuroscience, immunology, and oncology.
AbbVie has announced the groundbreaking of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. The facility is part of the company’s broader strategy to expand its U.S. manufacturing capabilities and network.
The new site will enhance AbbVie’s chemical synthesis capacity and bring selected API production from Europe and Asia back to the United States. It is expected to support the domestic supply of current and next-generation medicines across neuroscience, immunology, and oncology.
Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer at AbbVie, said: “Today’s groundbreaking is an important milestone in AbbVie’s ongoing campaign to accelerate biopharmaceutical innovation and manufacturing capabilities in the U.S.” She added that the company plans to invest more than $10 billion in capital over the next decade to expand U.S. manufacturing.
AbbVie currently employs 28,000 people in the U.S., including more than 11,000 in Illinois, where the company is headquartered. The new North Chicago investment builds on its existing network of 11 U.S. manufacturing sites, which collectively support over 6,000 jobs.
